Moteur de recherche d’entreprises européennes
Financement de l’UE (9 998 170 €) : Médecine dirigée par l’hôte dans l’infection fongique invasive Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Médecine dirigée par l’hôte dans l’infection fongique invasive
Despite novel treatment options and development of diagnostic tools invasive fungal infections (IFI) are still associated with an unacceptably high mortality and morbidity. Experts believe that a host directed approach is needed to overcome this problem. HDM-FUN proposes a transdisciplinary approach to identify host-pathogen factors (HPFs) needed for host directed medical interventions in IFI and will be the first of its kind. The overall concept is to identify host-pathogen factors in the setting of immunotherapy and prophylaxis that will allow the design for tailored novel therapeutic and preventive host-directed medicine approaches for patients with lethal invasive fungal infection in the intensive care. Specific objectives: 1. To identify host-pathogen factors that correlate with disease, and correlate them with preventive or immunotherapy- based strategies to stratify patients for personalized host-directed treatment options. 2. Two clinical trials of host-directed medicine approaches; an immunotherapy trial in patients with candidemia and a prospective observational trial for prophylaxis in patients with influenza at risk for aspergillosis. 3. To set-up a centrally managed biobank with samples of the patients enrolled in both clinical trials, and to standardize experimental procedures, protocols and centralize analysis. 4. To establish a unique infrastructure aimed to: explore host-directed medicine approaches in IFI, evaluate their impact on patients and health care, translate research efforts to clinical practice by designing point of care tests and teaching medical professionals. HDM-FUN brings together top scientists and clinical researchers to unravel host factors (genetics and transcription), immune modulators (metabolome, microbiome), and host pathogen interactions (genetics, metabolomics, immunology, signalling pathways, phagosome biogenesis, and inflammasome regulation) that determine the susceptibility and outcome of patients with fungal infection.
| Centre Hospitalier Universitaire Vaudois | 456 500 € |
| Duke University | 592 750 € |
| Hycult Biotechnology B.V. | 400 000 € |
| Idryma Technologias Kai Erevnas | 319 750 € |
| Imagine Institut des Maladies Genetiques Necker Enfants Malades Fondation | 633 124 € |
| Innovation Acta Srl | 350 500 € |
| Institut Pasteur | 692 185 € |
| Johann Wolfgang Goethe-Universitaet Frankfurt AM Main | 198 150 € |
| Julius-Maximilians-Universitat Wurzburg | 319 950 € |
| Katholieke Universiteit Leuven | 1 271 626 € |
| Leibniz-Institut FUR Naturstoff-Forschung UND Infektionsbiologie e. V. Hans-Knoll-Institut | 319 700 € |
| Stichting Radboud Universitair Medisch Centrum | 3 288 700 € |
| Stichting Radboud Universiteit | 0,00 € |
| The University Court of the University of Aberdeen | 320 010 € |
| Universidade do Minho | 319 625 € |
| Universita Degli Studi Di Perugia | 322 450 € |
| Universitatea de Medicina si Farmacie Iuliu Hatieganu Cluj-Napoca | 193 150 € |
| Universite Paris Cite | 0,00 € |
https://cordis.europa.eu/project/id/847507
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
